Efficacy & Safety of Repaglinide as Monotherapy or with Metformin in Achieving the Recommended Glycemic Targets of Type 2 Diabetes

N. S. Al-Kirwi, Esam; F. R. AL-Auqbi, Tawfeeq

	Efficacy & Safety of Repaglinide as Monotherapy or with Metformin in Achieving the Recommended Glycemic Targets of Type 2 Diabetes
Mustansiriya Medical Journal
Article 1, Volume 7, Issue 1, 2008, Pages 4-8
Authors
Esam N. S. Al-Kirwi; Tawfeeq F. R. AL-Auqbi
Abstract
Abstract Objectives To assess the efficacy and safety of Repaglinide in achieving the recommended glycemic targets in type 2 diabetes. Methods Six months prospective interventional study (before and after treatment) was carried out on 125 type 2 diabetics treated by Repaglinide with/without metformin. Patients were interviewed three times, at the begining, after three and six months each time they were examined physically and investigated thoroughly. Results Efficacy and safety parameters, fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated hemoglobin (HbA1c) had shown a significant statistical reduction to meet the recommended glycemic control targets of the American Diabetes Association (ADA) and very close to the International Diabetes Federation, European Diabetes Policy Group (IDF) at the consecutive interviews. Lipid profiles values, Total cholesterol, LDL-C, HDL-C, non-HDL-C, triglyceride and atherogenic index (TC/ HDL-C ratio) were achieved significant statistical improvements. Conclusions Repaglinide as monotherapy or in combination with metformin was safe, efficacious and well tolerated for lowering plasma glucose in type 2 diabetes, achieving the internationally recommended glycemic targets and improving the lipid profile values.

Statistics Article View: 118 PDF Download: 72